Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

By N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffié, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold and 2 more. Journal of Clinical Oncology, 2003

2,953 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/155dd6dd9236cae38680268cab043885ed7d90fe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Castelletti
2. J. Rasko
3. D. Yeo
4. N. van Zandwijk

Citations in the corpus

• Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma (2021, background): “Despite these clinical trials, pemetrexed/cisplatin has remained the only Food and Drug Administration (FDA)-approved chemotherapy combination, thus illustrating the difficulty in establishing effective therapies for MPM [9].”